Abstract 6P
Background
Lymph nodes (LN) act as central hubs for the orchestration of adaptive immune responses. A network of lymph node stromal cells (LNSC), including mesenchymal and endothelial cells, build a 3D network for immune cells to migrate and home to distinct niches in the LN. Within B cell non-Hodgkin lymphomas, indolent follicular lymphomas (FL) are characterized by subtle structural changes while the compartmentalization of the tissue remains present. In contrast, aggressive diffuse large B cell lymphomas (DLBCL) are defined by a complete loss of tissue organization indicating a potential role of LNSCs in tumorigenesis. While the morphological differences are well-known, the underlying molecular and cellular mechanisms remain poorly understood.
Methods
Here, we dissect the mechanisms underlying loss of structure in lymphomagenesis using combined single-cell transcriptome and spatially-resolved mapping approaches of LNSCs and immune cells.
Results
Using ultra-high plex immunofluorescence imaging, we characterized how lymph node cells organize into spatially distinct cellular neighborhoods, the disruption of which was congruent with lymphoma-induced remodeling. Using single-cell transcriptome data, we investigated the molecular programs driving this loss of organization. In DLBCL, chemokines relevant for immune cell organization were downregulated, while chemokines contributing to inflammation were upregulated, suggesting a phenotypic switch from a structural organized to an inflammatory and fibrotic state. In silico cell-cell interaction analysis indicated that besides the loss of mesenchyme-derived chemokine gradients, inflammatory immune cells outside of follicles turn into ectopic sources of these chemokines, an effect which likely contributes to the diffuse growth pattern of aggressive lymphomas. High expression of organizing chemokines was associated with better overall survival, this association being significant in FL and a trend in DLBCL.
Conclusions
Collectively, these data suggest that a reprogramming of the LN microenvironment triggers an imbalance in chemokine gradients, which underlies loss of tissue organization in aggressive lymphomas.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09